Welcome to our dedicated page for Scisparc SEC filings (Ticker: SPRC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SciSparc Ltd. (Nasdaq: SPRC) SEC filings page provides access to the company’s regulatory disclosures as a foreign private issuer. SciSparc files annual reports on Form 20-F and frequent current reports on Form 6-K, which together describe its clinical-stage pharmaceutical activities, capital structure, and material corporate events.
Recent Form 6-K filings highlight several categories of information. Transaction-related 6-Ks describe agreements such as the asset and share purchase arrangement through which SciSparc obtained a controlling interest in NeuroThera Labs Inc. and transferred its advanced clinical-stage pharmaceutical portfolio and its stake in SciSparc Nutraceuticals Inc. to NeuroThera. Other 6-Ks detail the sale of MitoCareX Bio Ltd. to N2OFF, Inc., the binding term sheet and definitive agreement to acquire a treasury of patents and trademarks for the MUSE endoscopic system from Xylo Technologies Ltd., and a framework agreement terminating a prior merger agreement with AutoMax Motors Ltd. and setting loan repayment terms.
Filings also cover capital markets and compliance matters, including inducement letter agreements with holders of existing warrants, under which warrant exercise prices were adjusted and SciSparc expects to receive gross proceeds for working capital and general corporate purposes. Another 6-K reports a Nasdaq notification that the company no longer met the minimum stockholders’ equity requirement for continued listing, and outlines the timeframe to submit a compliance plan.
In addition, SciSparc uses Form 6-K to furnish financial statements and MD&A, such as unaudited consolidated interim financial statements and management’s discussion and analysis for the six months ended June 30, 2025. Patent- and R&D-related press releases—covering NeuroThera’s opioid–N-acylethanolamine patent, MEAI-based depression patent applications, and the quantum computing-enabled 3D protein modeling initiative—are also incorporated by reference via 6-K exhibits.
On this page, users can review SciSparc’s 6-K submissions, including exhibits like binding term sheets, asset and share purchase agreements, and inducement letters, alongside its 20-F annual report. AI-powered tools summarize key points from these filings, highlight items such as equity transactions, IP acquisitions, and listing status updates, and help readers navigate complex transaction terms and risk disclosures without reading every page in detail.
SciSparc Ltd. reports that AutoMax Motors Ltd. has obtained a court-ordered pause in the approval process for their planned merger. On September 16, 2025, AutoMax filed a motion with the Jerusalem District Court under Israeli companies law, asking to stay proceedings related to its shareholders’ approval of the merger with SciSparc and a merger subsidiary.
The Court granted the request, staying the proceedings until September 30, 2025, or until AutoMax notifies the Court that conditions precedent to completing the merger have not been met, whichever comes first. AutoMax sought this stay because recent developments in its business operations raise uncertainty about its ability to satisfy the closing conditions for the merger.
SciSparc Ltd. reports that in August 2025 certain investors converted portions of previously issued convertible debentures into equity. The debentures were originally issued in an aggregate principal amount of $4.2 million and are convertible into ordinary shares. Based on conversion notices submitted by investors, the company issued 999,528 ordinary shares upon conversion of outstanding principal and accrued interest. After these issuances, SciSparc had 1,622,273 ordinary shares issued and outstanding as of August 28, 2025, and $175,000 principal amount of debentures remained outstanding.
SciSparc Ltd. reports that its shareholders have approved a merger with a leading parallel vehicle importer in Israel. The company also notes that shareholders of AutoMax, the target business, have approved merging AutoMax with SciSparc.
The report furnishes two press releases as exhibits describing these approvals and incorporates this information into multiple existing SciSparc registration statements on Forms F-3 and S-8, meaning the merger details become part of those offering documents going forward.
SciSparc Ltd. reports that its shareholders approved all proposals presented at an adjourned special general meeting held on August 26, 2025. The proposals were approved by the required majority under Israeli Companies Law and the company’s amended and restated articles of association, as described in the proxy statement/prospectus sent to shareholders.
The company also states that this report is incorporated by reference into several of its existing registration statements on Form F-3 and Form S-8, meaning those registration statements now include this update as part of their disclosed information.
SciSparc Ltd. convened a Special General Meeting of Shareholders on August 25, 2025, but the meeting was adjourned due to lack of quorum. The adjourned Special Meeting is scheduled for August 26, 2025 at 8:00 a.m. Eastern / 3:00 p.m. Israel time at the company’s Tel Aviv offices.
If a quorum is still not present within half an hour of the new start time, any shareholders present in person or by proxy, or who have delivered a proxy card, will constitute a quorum and may vote on the meeting matters. Proxy cards already delivered will be used at the adjourned meeting.
SciSparc Ltd. furnished a Form 6-K to update investors about a new development in its collaboration with Clearmind. The company reported that on August 7, 2025 it issued a press release titled “SciSparc-Clearmind Collaboration Leads to Publication of International Patent Application for Novel Combination Therapy Targeting Obesity and High Blood Sugar.” This indicates the partners are pursuing patent protection for a combination therapy aimed at metabolic conditions such as obesity and elevated blood sugar levels.
The Form 6-K also states that this update is incorporated by reference into SciSparc’s existing shelf registration statements on Form F-3 and its equity compensation registration statements on Form S-8, meaning the disclosure becomes part of those securities offering documents.